Vanderbilt Institute for Clinical and Translational Research Archives
Apr. 1, 2021—New investments in clinical programs at Vanderbilt University Medical Center are increasingly contingent upon studies to validate claims of benefit and the potential for scalability and spread.
Mar. 2, 2021—As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.
Oct. 8, 2020—A computer-based method developed at Vanderbilt University Medical Center that scans electronic medical records (EMRs) for genetic contributors to disease has been used for the first time to reveal the impact of race on health.
Jul. 23, 2020—Todd Rice, MD, MSc, has been appointed vice president for Clinical Trial Innovation and Operations in the Vanderbilt Institute for Clinical and Translational Research (VICTR).
Oct. 3, 2019—For patients in pediatric intensive care who are at high risk for acute kidney injury (AKI), giving clinicians automated decision support during the electronic order entry process increased the rate of blood testing for AKI by 9%.
Oct. 2, 2019—Vanderbilt investigators have identified 13 previously unknown drug compounds that cause false positive screenings for amphetamines, buprenorphine (an opioid), cannabinoids and methadone.
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Aug. 14, 2018—Medically underserved women in the Southeast diagnosed with breast cancer or ovarian cancer missed out on genetic testing that could have helped them and their relatives make important decisions about their health, according to new research from Vanderbilt-Ingram Cancer Center.